Explore our strategy and projects
to learn about the future of our company
Results FY 2023 (€/MLN)
1,148
Revenues
375
Adjusted EBITDA
224
Adjusted net profit
209
Free cash flow
Stock price
Discover morePress releases
11/11/24 - 7:38
Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®
05/11/24 - 16:27
Price sensitiveDiasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance
Presentations
20/11/24
Diasorin to Present at Jefferies London Healthcare Conference 2024
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments